Serving Up Accurate Test Results
Serving Up Accurate Test Results
Today, June 27th, sees the beginning of one of the four tennis majors – Wimbledon. Basking in the summer sun while lying on ‘Henman Hill’, this yearly tournament attracts spectators from all over the globe who want to watch the world’s best tennis players ply their skills on the revered centre court over the course of a two week period. But what exactly is the most important skill a tennis player can utilise? Well, many players have different strengths but the one skill that all of them must possess is the ability to serve – and accurately.
The ability to serve is vitally important as it allows the point to begin, serving accurately however allows the player to set the pace and ensure they are on the front foot. By making sure they serve more accurately, the player can be confident in their ability to win the point and the match.
Just like tennis, laboratories will aim to be accurate when ‘serving’ up their test results. Achieving accurate test results is what every lab strives for. With patient results on the line it is important for labs to use QC material that will assist them in obtaining the correct results, therefore keeping them clear of causing a ‘racquet’.
Randox Acusera is world renowned for delivering unbiased performance assessment. Our range of true third party controls are manufactured to the highest standard ensuring commutable samples that react to the test system in the same manner as a patient sample, ultimately allowing labs to be confident in the results they produce. Much like the serve in tennis that needs to fall within a target area, QC results should be as close as possible to the target and ideally should fall within +/- 2 SD from the mean. By falling within these limits a lab can be sure of accurate results and an acceptable performance.
Employ Acusera quality controls in your laboratory today and experience unrivaled confidence in your test results.
Get your slice of our control range here by contacting us at acusera@randox.com. We guarantee you will love us!
Randox celebrates women in engineering
Thurs 23rd June 2016 marks National Women in Engineering Day, an annual campaign that aims to highlight the role of women in engineering, and focus attention on the array of career opportunities available for women in this rewarding industry. The campaign is run by the Women’s Engineering Society (WES) whose goal is to ‘encourage women to participate and achieve as engineers, scientists and as leaders’. As a company who aim to inspire, and actively encourage women to enter careers in the areas of Science, Technology, Engineering and Maths (STEM), this resonates with us.
To show our appreciation of this campaign, we interviewed Randox Engineer, Maryrose McLoone from our Randox Teoranta team. Maryrose shared with us her journey into the industry of engineering…
How long have you worked in engineering?
I began working in Randox Teoranta after completing my undergraduate studies in Mechanical Engineering, and have been working here for the past year. Prior to this, as part of my undergraduate studies, I took a five month work placement as a Quality Intern at a medical device company.
How did you know a career in engineering was for you?
I have always been interested in maths and science, and the general STEM subjects. Engineering had been suggested to me by our Career Guidance Counsellor in secondary school due to my interest in maths. I hadn’t much experience with engineering related subjects prior to starting college but my undergraduate studies began with the basics, so everybody started on the same level.
How did you decide which area of engineering you wanted to pursue?
I chose Mechanical Engineering as it is a versatile form of engineering that would allow me to work in both the mechanical and biomedical engineering industries. My interest in working with medical devices came about during my college work placement. Through my placement I gained a great appreciation of engineering and the benefits it can have in the medical device industry.
Tell us about your role within the Randox Engineering team?
I work as a Mechanical Design Engineer. This involves designing and testing components and modules for clinical chemistry analysers. At the minute I am working alongside other Engineers from mechanical, electrical, and embedded systems, as well as Software Developers in the development of the RX misano test jigs which will be used for troubleshooting and to aid in QC procedures.
What skills have you gained with your career experience?
My role as a Design Engineer has allowed me to improve my skills in many areas such as design and testing, communication, organisation and time management skills, as well as gaining an understanding of the relevant medical device quality standards. My position involves working with a team of engineers from various engineering backgrounds, as well as working closely with quality and manufacturing to ensure the smooth transition from prototype to production.
What do you enjoy most about your job?
As a Design Engineer you are constantly coming up with new and creative solutions to problems. You can see your designs evolve from prototypes to completed projects. I find working in medical devices in particular to be a very fulfilling and highly rewarding job. You can be assured that your hard work is for a good purpose as it results in the creation of analysers which are used to conduct a wide variety of tests and perform important diagnoses. The design of clinical chemistry analysers involves careful consideration and attention to detail, an aspect which I enjoy.
My skills in the structure and organisation of tasks have developed from working in a highly regulated environment; such traits are extremely important when designing medical devices to ensure the production of quality products. As a Design Engineer working for Randox it is rewarding to be part of team that work together to improve healthcare through the development of clinical diagnostic solutions.
Do you work alongside any other women in the engineering department?
Yes, our R&D team comprises of Engineers in the areas of Mechanical, Electrical, and Embedded systems Engineering as well as Software Developers and Scientists. In our team there are women working in Embedded Systems, Software, and Science. Each team member has an important role in the design, development, and testing of our analysers. Embedded Systems Engineers and Software Developers work on developing and testing the software for our analysers. We also have a Scientist in our team who ensures our analysers can accurately run chemistry and helps in the verification and validation processes.
Proud to work as part of such a united team, Maryrose gives great insight into the role of a Design Engineer, and really highlights the depth of roles within the engineering industry; from System Engineers to Mechanical and Electrical Engineers. It is clear that women play a pivotal role in the Randox Engineering team, working together to design, develop and test our clinical diagnostic solutions.
Maryrose discussed her work as a Design Engineer within the RX series Engineering team. Her work on the RX misano has been crucial in the development of this new semi-automated analyser, details for which can be found below:
The RX misano is the newest analyser in the RX series of clinical chemistry analysers, and will be available for purchase soon. It is a semi-automated analyser designed with usability in mind; the screen has been positioned at an optimal viewing angle for the user, a touch button has been incorporated into the design to allow for the easy aspiration of sample, and, a 7” touch screen has also made the RX misano more user friendly than previous designs. The analyser software, developed by Randox, provides easy-to-use test screens and highlights any analytical problems to the user.
For more information, and to register your interest in the RX misano, please visit: therxseries.com/rx-altona
The RX misano is currently unavailable to purchase in Germany
MYTH: Only overweight people get type 2 diabetes, right?
The answer to this common myth is no. Let us tell you why…
As a condition that usually manifests later in life, type 2 diabetes is viewed by many as a self-inflicted disease caused by eating too much sugar and being overweight. Although obesity is strongly associated with type 2 diabetes it isn’t the only cause. In fact, many people of a healthy weight have type 2 diabetes, and similarly many overweight people do not. This is because an individual’s metabolic health can be affected by factors other than their weight.
Firstly, let’s define metabolic health; metabolic health refers to the body’s health at a cellular function, and one aspect of this is the body’s ability to utilise nutrients for energy. Within this insulin has an important function; insulin is a hormone produced by the pancreas and used by the body to regulate how glucose is used and stored. In some individuals, however, this is not the case; their pancreas may either not produce enough insulin, or may not be able to effectively use the insulin it produces, known as insulin sensitivity. High blood sugar level and type 2 diabetes is the effect of this.
Whilst obesity and lack of exercise are 2 of the most common reasons affecting metabolic state and causing type 2 diabetes, it is important to note that approximately 1 in 3 type 2 diabetics are undiagnosed. Therefore the causal factors of these individuals are not included in the statistics and therefore not accounted for in this statement. Other causal factors include family history, ethnicity, age, stress, inflammation, poor diet and visceral fat.
Let’s talk about a few of these factors…
Family history & ethnicity – Do genetics play a role?
Risk factors of type 2 diabetes includes family history and ethnicity; research(1) has found that there is a 1 in 7 risk of type 2 diabetes for children whose parents were diagnosed before the age of 50, and 1 in 2 risk for children if both parents have type 2 diabetes. Furthermore, research(2) has linked genetic mutation of the HMGA1 gene to an increased risk of type 2 diabetes in white Europeans; the study found that defects in the HMGA1 gene led to a drop in the body’s ability to make insulin receptors, thus leading to insulin resistance. In fact, 1 in 10 study participants with type 2 diabetes had a genetic mutation of the gene. Furthermore certain ethnic groups have been linked to increased risk of type 2 diabetes i.e. African Americans, Native Americans, Hispanic Americans and Asian Americans; some believe this may be due to genetics.
Chronic Stress
When the body is under stress, stress hormones such as cortisol are released. These hormones can affect the body’s blood glucose levels; for example, one of the primary functions of cortisol is to provide an immediate source of energy for the body, resulting in an increase of glucose supply to the blood. Individuals suffering chronic stress therefore have a constant production of cortisol, and chronically increased blood glucose levels as a result. This increases the risk of type 2 diabetes.
Chronic stress can lead to inflammation, which is another risk factor in the development of type 2 diabetes.
Inflammation
As the body’s natural response to injury, inflammation is the initial step in the healing process. Opening the blood vessels to allow free movement of the body’s natural healing substances to the affected site, it offers the body protection and fights off foreign substances such as germs and toxins. Inflammation is necessary to rid infections and heal wounds, however if the body suffers a chronic state of inflammation it can have damaging effects; chronic inflammation is caused by autoimmune conditions, allergies, chronic stress and conditions such as Crohn’s disease, and is linked to major diseases such as heart disease, arthritis and certain cancers. The link with type 2 diabetes is a result of inflammation causing insulin resistance, increasing the risk of type 2 diabetes.
Abdominal visceral fat
Abdominal visceral fat is the fat which surrounds the internal organs in the abdominal cavity. High levels of abdominal visceral fat are associated with insulin resistance and therefore, high risk of diabetes. Abdominal visceral fat can be found in individuals of all shapes and sizes, and regardless of ‘healthy’ BMI high visceral fat levels can still occur. This is because BMI doesn’t take into account muscle mass or other factors including gender and ethnicity. This presents an issue as those with a ‘healthy’ BMI may unknowingly still be at risk of diabetes. Similarly those with high muscle mass, who are determined ‘overweight’ based on BMI, may worry that they are at risk of diabetes, when in fact their weight isn’t putting them at risk. Determining levels of abdominal visceral fat is a much better indication of health than BMI.
Overall risk of type 2 diabetes is correlated with genetic, environmental and lifestyle factors. Whilst some impact more than others, it is important to recognise that there are numerous factors related to type 2 diabetes, and rid the myth that obesity and a high sugar diet high are the only causal factors.
Help set the record straight by sharing this article:
References:
(1) American Diabetes Association (2014) Genetics of Diabetes. Found online at diabetes.org/diabetes-basics/genetics-of-diabetes.html
(2) Brunetti et al (2011) Functional Variants of the HMGA1 Gene and Type 2 Diabetes Mellitus. Journal of the American Medical Association (JAMA); 305 (9):903-912.
If you are worried about your blood glucose levels, or risk of diabetes, ask your doctor for these tests:
- Glucose, HbA1c and Fructosamine to assess your blood glucose levels
- CRP to determine chronic inflammation with additional testing of SPLA2-IIA levels to determine vascular inflammation
- Adiponectin to assess your level of abdominal visceral fat. High levels of abdominal visceral fat can indicate metabolic syndrome and pre-diabetes.
For more information on diabetes testing visit our dedicated diabetes reagents page.
For health professionals:
Adiponectin is a protein which regulates the metabolism of lipids and glucose and influences the body’s response to insulin. Low levels of Adiponectin are correlated with increased CRP (increased inflammation), higher levels of triglycerides and insulin resistance. As a result of increased insulin resistance and inflammation, low levels of Adiponectin can indicate metabolic syndrome.
For more information please visit our dedicated Adiponectin page or view our full range of diabetes tests.
SPLA2-IIA is a highly specific marker of atherosclerotic plaque inflammation, and has a direct role in the formation of rupture-prone atherosclerotic plaque. Increased concentrations of SPLA2-IIA have been linked with increased risk of cardiocerebrovascular events. As a highly specific marker of vascular inflammation, it complements tests such as hsCRP, and can be used to improve the risk assessment of patients with moderate to high risk of CVD, in particular those with metabolic syndrome such as insulin resistance.
Further reading: Sertić et al (2010) Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease? Acta Med Croatica. 64(4):237-45
Randox SPLA2-IIA will be available soon. To register your interest please view our dedicated SPLA2-IIA page.
Measurement of Uncertainty Educational Guide
Measurement of Uncertainty relates to the doubt that exists for the result of any measurement. For every measurement there is always a margin of doubt and therefore we need to ask ‘How big is the margin?’ and ‘How significant is the doubt?’.
In a hospital or healthcare environment, the clinician must be certain that any change identified in a patient’s test results is not a change to the laboratory test system but a change to the patient’s status. This is especially critical at clinical decision levels. Randox Quality Control has developed a guide to Measurement of Uncertainty in response to the demand for more information on the topic within the industry. This guide outlines what Measurement of Uncertainty is, how to measure uncertainty, factors which affect uncertainty and it’s sources.
Request your copy today!
Hearing Loss Linked with Common Household Products, Study Finds
Hearing loss is often associated with old age, tinnitus or balance disorders. However, studies show that anyone can be affected by hearing loss, at any age if exposed to a chemical present in many common household products.
Chances are, you take your senses for granted. Associated generally with deterioration in old age, we never assume we will go deaf or blind in our younger years. Nevertheless, approximately 3 million children in the USA suffer from hearing loss and this number is on the rise. (CHC, 2016)
In 2006, a study was released detailing the mysterious premature hearing loss of a collection of employees in a manufacturing site in Taiwan, specialising in adhesive materials. Chang, Chen, Lien, and Sung narrowed the phenomenon that was the loss of the worker’s auditory sense down to the responsibility of one chemical: Toluene.
Chemical-induced hearing loss, also known as “ototoxicity”, can affect anyone of any age and today, there are over 200 known ototoxic medications on the market known to cause damage to the inner ear containing chemicals largely known to induce ototoxicity such as Syrene and Xylene.
However, sold in many high-street shops, you’ll find the biggest player in the cause of ototoxicity: Toluene. Toluene is a major component of paints, varnishes, petroleum, printing inks, degreasers, adhesives, cigarette smoke, glues, thinners, and plastics. Exposure to Toluene, such as inhalation, ingestion or skin contact, is known to cause not only hearing loss, but commonly can be a factor in causing Tinnitus, Dermatitis, and vision impairment. In general, the component can wreak havoc for the central nervous system and prolonged exposure to high concentrations of the colourless liquid may result in loss of consciousness, and may even be fatal.
Wanisiusiow, whose findings were conducted using the RX series’ RX daytona and a Randox creatinine kit stated, “Toluene is undoubtedly one of the most widely used organic solvents in industry.” But how does Toluene do it? Wanisusiow goes on to state, “As far as we know, there are two major mechanisms which might explain toluene-induced hearing loss. Firstly, a poisoning of Deiters and Hensen’s cells, which are both important to maintain the K+ homeostasis in the vicinity of outer hair cells. Secondly, an oxidative cell injury, such as lipid peroxidation.”
An interesting point uncovered in this study is that suffering the severe side-effect of Toluene seems to be species-specific. The original experiment, carried out on rats, displayed expected symptoms of ototoxicity. However, guinea pigs reacted differently. The study speculates: The half-life of toluene is longer in the rat than in the guinea pig. This might be one way to explain the difference in cochlear sensitivity to toluene between rats and guinea pigs but likely not the only one.
So, what is it in the genetic makeup of guinea pigs, that rats do not possess, that could fight the negative effects of Toluene? Could learning what causes guinea pigs immunity be beneficial to our research into hearing loss?
For more, follow the RX series on Facebook, Twitter, Instagram and LinkedIn.
Importance of Using Third Party Controls
Importance of using third party controls
The importance of using third party controls cannot be overlooked. Using these controls can help to identify instrument, reagent and procedural errors which, if undetected could lead to the reporting of incorrect patient results!
What is a third party control?
ISO 15189:2012 states “the use of third party control materials should be considered, either instead of, or in addition to, any control materials supplied by the reagent or instrument manufacturer.” True third party controls are not optimised for use with a specific reagent or test system and therefore are renowned for delivering unbiased performance assessment with any instrument/method. The manufacturers of third party controls will usually assign values based on data collected from thousands of independent reference labs – thus ensuring the availability of statistically valid data for a wide range of platforms. Due to their independent nature and objectively assigned values you can be sure that third party controls will provide unbiased error detection across multiples platforms and methods.
First party control
Conversely, first party controls are analyser dependent controls that are supplied by the instrument/reagent manufacturer and are optimised specifically for use with the manufacturers test system and therefore will often mask weaknesses which could lead to the release of incorrect patient test results. These dependent controls are considered to lead to perceived accuracy and a biased assessment of performance.
Acusera third party controls
The Randox Acusera range of multi-analyte controls are true third party. Our controls have been designed to deliver an independent, unbiased assessment of performance with instrument or method. Our unique value assignment process employs thousands of independent laboratories ensuring statistically valid targets are available for most laboratory instruments. The availability of multi-analyte, multi-instrument controls with a shelf life of up to 4 years not only ensures continuity of lot supply but will significantly reduce costs and preparation time by reducing the need for multiple instrument specific controls.
Case Study 1
A laboratory running Acusera Immunoassay Premium Plus Control reported their QC results for Thyroglobulin were four times higher on the their main analyser compared to other systems.
They ran the instrument manufacturer’s control alongside the Acusera control but it did not show the same problem.
After reviewing EQA data, the Randox Technical Services team confirmed there was a significant difference in results compared to other instruments.
The customer contacted their instrument manufacturer, who advised of a positive bias with several batches of reagent.
In summary, the Randox Immunoassay Control detected a shift in results that the instrument dedicated control did not.
Case Study 2
A laboratory noticed an increase in native patient sample result recovery of around 15-20%. The lab were running their Gentamicin reagent along with a TDM calibrator. Over recovery was also noted for EQA samples however, the issue had not been detected with their current control set.
The laboratory got in touch with Randox about the use of our controls and if they would experience the same problems with our controls as they are with their current provider. We assured the laboratory that our controls were true third party and the unique 100% human serum matrix would provide a sample as close as possible to that of the patient.
The laboratory decided to test a sample of Acusera TDM control and were delighted with the results. They purchased some of our therapeutic drug controls and have yet to experience any increase in the result recovery of patient samples highlighting the need to use true third party controls.
Summary
This case study once again highlights how important running true third party controls is to a laboratory. It can be the difference between them reporting accurate and reliable patient test results and reporting incorrect results that could lead to a misdiagnosis which could be fatal to the patient on the receiving end.
Ensure your laboratory is using true third party controls by contacting Randox today. Request a quote from one of our QC consultants at acusera@randox.com
What is the relationship between kidney function and abdominal fat?
It is widely understood that hypertension and diabetes are two of the most common causes of chronic kidney disease (CKD), a long-term condition where the kidneys do not work effectively. But what about abdominal fat?
Abdominal fat contributes to risk of diabetes and hypertension, and with these being the most common causes of CKD, it’s natural to associate abdominal fat with CKD, isn’t it? A new study has recently been published which examines this.
The study(1) aimed to examine the relationship between kidney function and abdominal fat; the researchers wanted to discover if abdominal obesity is associated with early markers of CKD in a young healthy population, and whether these associations differ by race and/or ethnicity.
As symptoms of CKD are not usually present until the condition reaches an advanced stage, blood and urine tests are relied on to detect the condition at earlier stages, and enable treatment to begin as early as possible. The identification of more indicators to enable this condition to be detected as early as possible is of interest, particularly due to 10% of the world’s population being affected by CKD(2).
The study involved the analysis of data gained from The National Health and Nutrition Examination Survey (NHANES) in the US between 1999 and 2010. This included health, lifestyle and nutritional information from 6918 young adults aged 20-40 years; factors included height, weight, waist circumference, blood pressure and blood/urine samples for analysis of components including albumin, CRP, glucose, insulin, creatinine etc.
The researchers of the study defined abdominal obesity by gender criteria of waist circumference, and markers of CKD included estimated glomerular filtration rate and albuminuria ≥30 mg/g. Risk of CKD was analysed within strata of race and in subgroups of those with normal blood pressures, normal blood sugar levels and normal insulin sensitivity. Awareness of CKD was assessed in participants with albuminuria.
The study concluded that abdominal obesity in young adults, especially in Mexican-Americans, is independently associated with early markers of kidney dysfunction even in those with normal blood pressures, glucose levels and insulin sensitivity.
References:
- Sarathy H et al. (2016) Abdominal Obesity, Race and Chronic Kidney Disease in Young Adults: Results from NHANES 1999-2010. PLoS ONE 11(5): e0153588. doi:10.1371/journal.pone.0153588
- World Kidney Day (2016) Chronic Kidney Disease. Online at: http://www.worldkidneyday.org/faqs/chronic-kidney-disease/
Please note:
With the prevalence of obesity, greater awareness of CKD is needed to protect the youth from premature kidney dysfunction. Those at high risk of CKD should be screened every year. This includes patients with high blood pressure (hypertension), diabetes, or a family history of CKD. If symptoms are experienced visit your GP – symptoms of advanced CKD include tiredness; swollen ankles, feet or hands (due to water retention); shortness of breath; nausea; and blood in the urine.
For health professionals: The adiponectin test from Randox can accurately assess levels of abdominal visceral fat, independent of age, race or fitness level. Assessing adiponectin, and therefore visceral fat levels, can help assess risk of CKD, as well as a range of other illnesses such as pre-diabetes, CVD and various cancers. Contact us now for further information.
Manage Your Laboratory Effectively with Randox Quality Control
Manage Your Laboratory Effectively with Randox Quality Control
With Euro 2016 starting today the final squads for each country participating have been carefully selected. Confirming those players who made the squad were the managers – managing their team effectively is a tough job but when done right it can be rewarding. However, getting the squad and team wrong can have major repercussions.
Linking Football to your Laboratory
Is the idea of managing a “team” effectively sounding familiar? You could be forgiven for not seeing the link between a football team and laboratory in this scenario. By managing your laboratory effectively you can be sure that accurate and reliable results are being reported whilst keeping your costs at a minimum and reducing the time spent preparing your controls. The same can be said for a football team – if you get the squad right then the players perform well and therefore produce better results and performances.
In terms of managing your laboratory effectively the best option is to ensure you have all areas of clinical testing covered, internal quality control, an inter-laboratory data management programme and also external quality assessment.
What can Randox Quality Control offer?
With an extensive portfolio combining true third party controls (Acusera Quality Control), inter-laboratory data management (Acusera Live Online 24.7) and the world’s largest EQA scheme (RIQAS), Randox can uniquely provide a complete Quality Control package to help “manage laboratories effectively”. Unrivaled confidence in patient results comes from using our complete package, our IQC and EQA will also deliver effective consolidation and significant cost savings, while implementation of Acusera 24.7 Live Online will allow at-a-glance performance assessment.
Appoint Randox to help you manage your laboratory and ensure accurate and reliable results enabling you to sit back, watch Euro 2016 and roar your country to victory.
To request a visit from a QC consultant contact us via acusera@randox.com
Laboratory Accreditation sees rise in the use of Third Party Quality Controls
A recent report published by Markets and Markets called “In Vitro Diagnostics (IVD) Quality Controls Market” has highlighted the significant growth within the Quality Control market, with further growth expected within the next 4 years, estimating that the IVD QC market will be worth $979 million. The report is crediting this growth to “the increasing number of accredited clinical laboratories and growing adoption of third-party quality controls”. It also indicates an anticipated growth of 4.7% CAGR between 2015 -2020 for third party quality controls. The adoption of third party controls is particularly interesting, as a survey conducted by Randox in 2015 found that only 35% of respondents felt that the most important feature when selecting quality controls for the laboratory was that they were third party, with stability being the top choice. This highlights the influence accreditation is having within the IVD market.
Why have these been influential?
Accreditation to ISO 15189:2012, and other similar standards, is becoming mandatory in many countries. Laboratories are becoming accredited to highlight the accuracy and reliability of the patient results they are releasing. Furthermore such accreditation standards and the industry regulatory bodies, like CAP, CLSI and so on, are recommending the use of third party controls. This is supported by ISO 15189:2012 which states, “the use of third party control materials should be considered, either instead of, or in addition to, any control materials supplied by the reagent or instrument manufacturer”. The report states that third party controls “offer various advantages over other types” of quality controls, this includes a longer shelf life and long term quality monitoring.
What can Randox Quality Control Offer?
The Acusera range of quality controls can be described as true third party or independent controls. Unlike first party controls or semi dependent controls they are manufactured independently of any instrument or reagent and thus are designed to deliver an unbiased assessment of analytical performance across all platforms while also meeting ISO 15189:2012 recommendations. To assist with the other requirements of ISO 15189:2012 each control is 100% commutable, ensuring a matrix that will react to the test system in the same manner as a patient sample. It should also be noted that the entire Acusera quality control range has been manufactured in line with clinically relevant decision levels. Employing controls that cover the entire clinical range will eliminate the need for separate low/high controls ultimately reducing costs while also ensuring accurate instrument performance. By employing any one of our Acusera Controls in your laboratory you could minimise costs & limit the time spent reassigning values after each lot change, highlighting just some of the additional benefits of employing a third party control.
To request a visit from a QC consultant contact us via acusera@randox.com
Is your Aspirin treatment effectively preventing thrombotic stroke?
The Stroke Association works to improve stroke prevention, treatment and care with a vision for a world where there are fewer strokes. They host Stroke Awareness Month every year and “Make May Purple” to raise awareness of the ways to lower the risks of taking a stroke and to help those affected by it.
What is a stroke?
For the brain to function properly, it needs the oxygen and nutrients provided by the blood. Stroke occurs when a blood vessel in the brain bursts or, more commonly, when a blockage develops which leaves the supply of the blood to the brain limited or completely obstructed and without treatment; cells in the brain quickly begin to die.
If an individual is at risk or has suffered from a stroke before, medication is often recommended by doctors to lower the risk. Anti-platelet drugs, including Aspirin, keep platelets in the blood from sticking together and forming clots possibly preventing another stroke.
However, there are risks to taking Aspirin every day…
There can be risks of taking Aspirin and some experts do not recommend it if the individual hasn’t already had a stroke. The benefits of taking daily Aspirin therapy don’t outweigh the risk of bleeding in people with a low risk of strokes; although the higher the risk of stroke, the more likely it is that the benefits of daily Aspirin outweigh the risk of bleeding.
Taking daily Aspirin may help to reduce clot-related stroke but it also may increase the risk of a bleeding stroke known as haemorrhagic stroke. Daily Aspirin may also increase the risk of gastrointestinal bleeding, if an individual has a bleeding ulcer or if they are bleeding anywhere else in the gastrointestinal tract, taking Aspirin will cause it to bleed more. Also some individuals can be allergic to Aspirin and if they take any it can trigger a serious allergic reaction.
Not everyone responds in the same way to Aspirin!
For a number of reasons including genetic factors; other medications; dosage problems; diabetes; and elevated cholesterol, not all patients respond in the same way to Aspirin therapy. Aspirin resistance is a serious clinical problem and is estimated to affect up to 30% of patients on a low dosage. It is vital that Aspirin resistance is recognised as these patients may need their treatment altered to prevent dangerous clotting.
The TxBCardio™ test helps to identify patients who have a sub-optimum response to their Aspirin therapy. Patients who have a sub-optimum response to their Aspirin therapy are three times more likely to die from a stroke than those who respond positively to such therapy.
This Stroke Awareness Month, we are encouraging the testing of at-risk individuals to ensure that they are responding in the correct way to Aspirin therapy, by taking the TxBCardio™ test! This will not only help the tailoring of treatment to reduce the risk of stroke, but it will also ensure that patients are not exposed to any unnecessary risk of side-effects associated with daily Aspirin consumption.
For health professionals
The primary action of Aspirin is to inhibit the production of thromboxane in the blood, a chemical which helps to cause blood clotting. However, methods of directly measuring the level of thromboxane in blood are unreliable, and so not widely used. Randox TxBCardio™ measures a direct urinary metabolite of thromboxane, 11dhTxB, therefore providing a reliable and stable measure of a patient’s response to their daily Aspirin therapy. This test is available on most automated biochemistry analysers.
Contact us now to request a brochure or kit insert.
